Hovione and H&T Presspart Extend Partnership for Dry Powder Inhalation Formulation Delivery
Presspart will still be responsible for the manufacturing of the Sunriser device.
Hovione and H&T Presspart have partnered to advance the development of Presspart’s Sunriser Capsule-based Dry Powder Inhaler platform. The companies plan to work together to develop the Sunriser Dry Powder Inhaler, which is flexible enough to address the challenges of carrier-based and spray-dried engineered formulations, according to the press release.
A part of the development agreement finds Hovione being an exclusive partner with Presspart to use the Sunriser device in engineered formulations for dry powder inhalation. Additionally, Presspart will still be responsible for the manufacturing of the Sunriser device.
"New inhalable therapies are often requiring delivery of higher doses of cohesive and sensitive powders. Our priority is to ensure maximum efficiency in delivering these drugs to the right locations in the lung,” said Jean-Luc Herbeaux, PhD, CEO of Hovione, in a press release. “We are thrilled to expand our current partnership with Presspart and combine our expertise in the fields of engineered particles and inhalers for the benefit of our customers and patients.”
Source: Hovione
Novartis Acquisition of Regulus Therapeutics is Complete
June 25th 2025A key property included in the acquisition is farabursen, an investigational next-generation oligonucleotide targeting the microRNA miR-17 with preferential kidney exposure, intended to treat people with autosomal dominant polycystic kidney disease.
